Arrhythmia Recognition and Management: A Clinical Approach

Cardiac arrhythmias represent deviations from normal sinus rhythm, encompassing abnormalities in heart rate, rhythm, or conduction. These disorders affect millions globally and range from benign variants to life-threatening emergencies requiring immediate intervention. Understanding arrhythmia recognition and management is crucial for medical practitioners across all specialties.

The normal cardiac conduction system originates at the sinoatrial (SA) node, generating impulses at 60-100 beats per minute. These impulses travel through the atria, reach the atrioventricular (AV) node, and proceed via the His-Purkinje system to ventricular myocardium. Arrhythmias arise from disorders of impulse formation (automaticity), impulse conduction, or both.

Classification of Arrhythmias:

Arrhythmias can be hemodynamically stable or unstable. Unstable arrhythmias present with hypotension (systolic BP <90 mmHg), altered mental status, chest pain, or signs of shock, requiring immediate cardioversion or other urgent interventions. Stable arrhythmias allow time for diagnostic evaluation and pharmacological management.

The approach to arrhythmia management follows the ABCDE protocol: Airway, Breathing, Circulation, Disability, and Exposure. Continuous cardiac monitoring, 12-lead ECG, and assessment of hemodynamic status guide initial management decisions. Key factors influencing treatment include arrhythmia type, hemodynamic stability, underlying cardiac disease, and patient symptoms.

Risk stratification considers factors such as left ventricular ejection fraction, presence of structural heart disease, electrolyte abnormalities, and medication effects. Patients with reduced ejection fraction (<40%) or significant structural heart disease require more aggressive monitoring and treatment due to increased risk of sudden cardiac death.

Atrial fibrillation (AF) is the most common sustained arrhythmia, affecting over 30 million people worldwide. It results from multiple reentrant wavelets in the atria, leading to irregular ventricular response and loss of effective atrial contraction.

ECG Characteristics:

• Absence of distinct P waves
• Irregularly irregular RR intervals
• Fibrillatory waves (f-waves) with varying amplitude
• Ventricular rate typically 120-180 bpm (untreated)

Classification:

• Paroxysmal: Self-terminating within 7 days
• Persistent: Lasting >7 days or requiring intervention
• Long-standing persistent: Continuous AF >12 months
• Permanent: Accepted AF with no further rhythm control attempts

Management Algorithm:

AF Patient Presentation | Hemodynamically unstable? | Yes ─────→ Immediate electrical cardioversion | No | Rate Control vs Rhythm Control? | ┌─────────────────┬─────────────────┐ Rate Control Rhythm Control | | Beta-blockers Antiarrhythmics CCBs (diltiazem) (amiodarone, flecainide) Digoxin Electrical cardioversion

Rate Control Strategy: Target resting heart rate <110 bpm for most patients. First-line agents include:

• Metoprolol: 25-100 mg BID
• Diltiazem: 120-360 mg daily
• Digoxin: 0.125-0.25 mg daily (limited to sedentary patients)

Rhythm Control Strategy: Considered for symptomatic patients, younger age, first episode, or when rate control fails. Antiarrhythmic selection depends on structural heart disease:

• No structural heart disease: Flecainide, propafenone, sotalol
• Structural heart disease: Amiodarone, dronedarone

Anticoagulation: Stroke risk assessment using CHA₂DS₂-VASc score:

• Score ≥2 (men) or ≥3 (women): Anticoagulation recommended
• Options: Warfarin (target INR 2.0-3.0) or DOACs (apixaban, rivaroxaban, dabigatran)
• Bleeding risk assessment using HAS-BLED score guides decision-making

Supraventricular tachycardia encompasses several arrhythmias originating above the ventricles, most commonly AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT). These arrhythmias typically present with sudden onset and termination of rapid, regular heart rates.

ECG Characteristics:

• Heart rate 150-250 bpm
• Narrow QRS complexes (<120 ms)
• Regular rhythm
• P waves may be absent, inverted, or buried in QRS

Types of SVT:

Acute Management Algorithm:

SVT with narrow QRS | Hemodynamically stable? | No ──────→ Synchronized cardioversion (50-100J) | Yes | Vagal Maneuvers (Valsalva, carotid massage) | Successful? ──Yes──→ Monitor | No | Adenosine 6mg IV push | Successful? ──Yes──→ Monitor | No | Adenosine 12mg IV push | Successful? ──Yes──→ Monitor | No | Consider: - Beta-blockers - Calcium channel blockers - Amiodarone - Cardioversion

Vagal Maneuvers:

• Valsalva maneuver: 15-second strain phase
• Carotid sinus massage: 5-10 seconds (contraindicated if carotid bruit)
• Cold water facial immersion
• Effective in 20-40% of cases

Adenosine Administration:

• First dose: 6 mg IV push followed by saline flush
• Second dose: 12 mg IV push if first dose ineffective
• Half-life: <10 seconds
• Contraindications: Asthma, COPD, high-grade AV block
• Side effects: Chest pain, dyspnea, flushing (transient)

Chronic Management:

• Catheter ablation: First-line for recurrent symptomatic SVT
• Pharmacologic therapy: Beta-blockers, calcium channel blockers for prevention
• Patient education: Recognition of symptoms, vagal maneuvers

Ventricular tachycardia (VT) is a potentially life-threatening arrhythmia characterized by rapid ventricular rate originating below the AV node. It represents a medical emergency requiring immediate recognition and treatment due to risk of hemodynamic collapse and degeneration to ventricular fibrillation.

ECG Characteristics:

• Heart rate >100 bpm (typically 150-250 bpm)
• Wide QRS complexes (>120 ms)
• AV dissociation (when visible)
• Regular or slightly irregular rhythm

Classification:

• Sustained VT: Duration >30 seconds or requiring termination
• Non-sustained VT: Duration <30 seconds, self-terminating
• Monomorphic VT: Uniform QRS morphology
• Polymorphic VT: Varying QRS morphology (including Torsades de Pointes)

Differential Diagnosis of Wide Complex Tachycardia:

Management Algorithm:

Wide Complex Tachycardia (Suspected VT) | Patient has pulse? | No ──────→ VF/Pulseless VT Protocol | (Immediate defibrillation) Yes | Hemodynamically stable? | No ──────→ Synchronized cardioversion | (100-200J biphasic) Yes | Monomorphic VT? | Yes ────→ Amiodarone 150mg IV over 10min | then 1mg/min infusion No | Polymorphic VT? | Normal QT ──→ Treat as Monomorphic VT | Long QT ───→ Torsades de Pointes Protocol (Magnesium sulfate 2g IV)

Pharmacologic Management:

• First-line: Amiodarone 150 mg IV over 10 minutes, then 1 mg/min for 6 hours, then 0.5 mg/min
• Alternative: Lidocaine 1-1.5 mg/kg IV bolus, then 1-4 mg/min infusion
• Procainamide: 20 mg/min IV until arrhythmia suppression, hypotension, or QRS widening >50%

Torsades de Pointes Management:

• Magnesium sulfate 2 g IV over 1-2 minutes
• Correct electrolyte abnormalities (potassium >4.0 mEq/L)
• Discontinue QT-prolonging medications
• Consider overdrive pacing or isoproterenol

Long-term Management:

• ICD implantation for survivors of sustained VT/VF
• Catheter ablation for recurrent VT
• Beta-blockers for ischemic cardiomyopathy
• Amiodarone for heart failure patients

Heart blocks represent conduction abnormalities within the cardiac conduction system, ranging from mild delays to complete AV dissociation. Understanding the classification and management of heart blocks is essential for appropriate patient care and prevention of sudden cardiac death.

Classification and ECG Features:

First-Degree AV Block:

• PR interval >200 ms
• Every P wave conducted to ventricles
• Usually benign, no specific treatment required

Second-Degree AV Block:

Type I (Wenckebach):

• Progressive PR prolongation until P wave not conducted
• Usually occurs at AV node level
• Often benign unless symptomatic

Type II (Mobitz II):

• Fixed PR interval with sudden non-conducted P waves
• Usually infranodal (His-Purkinje system)
• High risk of progression to complete heart block

Third-Degree (Complete) AV Block:

• Complete AV dissociation
• Independent atrial and ventricular rhythms
• Escape rhythm determines ventricular rate

Management Algorithm:

Heart Block Diagnosis | Symptomatic or High-Risk? | ┌─────────────┴─────────────┐ Yes No | | Permanent Pacemaker Observation | ↓ DDD/DDDR preferred Serial monitoring | ↓ Immediate if: Consider pacing if:

• Complete heart block - Progression
• Type II 2nd degree - Development of symptoms
• Symptomatic bradycardia - Pauses >3 seconds

Indications for Permanent Pacing:

Class I (Indicated):

• Third-degree AV block with symptoms or ventricular rate <40 bpm
• Second-degree Type II AV block
• Alternating bundle branch blocks
• First- or second-degree AV block with symptoms clearly related to block

Class II (Reasonable):

• Asymptomatic third-degree AV block with ventricular rate >40 bpm
• Asymptomatic Type II second-degree AV block with wide QRS
• First-degree AV block with left ventricular dysfunction and PR >300 ms

Temporary Pacing Indications:

• Hemodynamically significant bradycardia unresponsive to atropine
• Bridge to permanent pacemaker
• Drug-induced reversible AV block
• Perioperative management

Pharmacologic Management:

• Atropine: 0.5-1.0 mg IV (maximum 3 mg) for symptomatic bradycardia
• Isoproterenol: 2-10 μg/min IV for temporary rate support
• Dopamine: 5-20 μg/kg/min for hemodynamic support

Bundle Branch Blocks:

• Right Bundle Branch Block (RBBB): QRS >120 ms, rsR' in V1, wide S in I, aVL, V6
• Left Bundle Branch Block (LBBB): QRS >120 ms, broad R waves in I, aVL, V5-V6, absent Q waves
• Bifascicular block: RBBB + left anterior or posterior fascicular block
• Trifascicular block: Bifascicular block + first-degree AV block

Electrical cardioversion and defibrillation are critical interventions for managing life-threatening arrhythmias. Understanding proper technique, energy selection, and timing is essential for successful arrhythmia termination and patient safety.

Definitions:

• Cardioversion: Synchronized electrical shock delivered during QRS complex
• Defibrillation: Unsynchronized electrical shock for pulseless rhythms

Indications for Immediate Cardioversion:

• Hemodynamically unstable tachyarrhythmias
• Acute heart failure due to arrhythmia
• Ongoing chest pain with tachyarrhythmia
• Altered mental status due to arrhythmia

Cardioversion Protocol:

Elective Cardioversion Preparation | Anticoagulation Status? | ┌─────────────┴─────────────┐ AF >48h or unknown AF <48h duration | | 3 weeks anticoagulation Proceed with before and 4 weeks after cardioversion | | OR | TEE to exclude thrombus | | ┌─────┴─────┐ | Yes No | Proceed Anticoagulate | | ↓ | └─────────┴─────────────────┘ | Cardioversion

Energy Selection:

Cardioversion Procedure:

1. Preparation:

   • NPO status (minimum 6 hours for elective procedures)
   • IV access and continuous monitoring
   • Emergency airway equipment available
   • Anesthesia/sedation (propofol, etomidate, midazolam)

2. Pad Placement:

   • Anteroapical: Right sternal border, cardiac apex
   • Anteroposterior: Anterior chest, posterior left subscapular
   • Ensure good skin contact, remove hair if necessary

3. Synchronization:

   • Activate sync mode for all rhythms except VF/pulseless VT
   • Confirm R-wave sensing before delivery
   • Charge and deliver shock during expiration

Defibrillation for Pulseless Rhythms:

• VF/Pulseless VT: Immediate defibrillation at maximum energy
• Biphasic defibrillators: 120-200 J initial shock
• Monophasic defibrillators: 360 J
• CPR: 2 minutes between shocks, minimize interruptions

Complications and Management:

• Embolic events: Risk reduced by appropriate anticoagulation
• Skin burns: Proper pad placement and gel/paste application
• Myocardial damage: Rare with modern biphasic waveforms
• Arrhythmia induction: May precipitate different arrhythmias
• Respiratory depression: Monitor post-procedure, especially after sedation

Post-Cardioversion Care:

• Continuous cardiac monitoring for 4-6 hours
• Assessment of hemodynamic status
• 12-lead ECG to confirm rhythm
• Continue anticoagulation as appropriate
• Long-term rhythm control strategy

Effective arrhythmia management requires systematic approaches that prioritize patient stability, identify underlying causes, and implement appropriate interventions. This section provides integrated algorithms for common clinical scenarios.

Universal Arrhythmia Assessment:

Arrhythmia Detected | Assess ABCs (Airway, Breathing, Circulation) | Obtain 12-lead ECG + Continuous monitoring | Hemodynamically stable? | ┌─────────────┴─────────────┐ Unstable Stable | | Immediate cardioversion Identify rhythm | | Consider sedation Rate/rhythm control | | Treat underlying cause Anticoagulation

Hemodynamic Instability Indicators:

• Systolic BP <90 mmHg
• Altered mental status
• Chest pain or acute heart failure
• Signs of shock (cool, clammy skin; decreased urine output)

Narrow Complex Tachycardia Algorithm:

Narrow QRS Tachycardia (QRS <120ms) | Regular or irregular? | ┌─────────────┴─────────────┐ Regular Irregular | | SVT vs. Sinus tachycardia Atrial fibrillation | Multifocal atrial tachycardia Vagal maneuvers → Adenosine Rate control | | If refractory: Consider cardioversion

• Beta-blockers if unstable
• Calcium channel blockers |
• Cardioversion Anticoagulation

Wide Complex Tachycardia Algorithm:

Wide QRS Tachycardia (QRS ≥120ms) | VT vs. SVT with aberrancy? | Assume VT if uncertain | Regular or irregular? | ┌─────────────┴─────────────┐ Regular Irregular | | Monomorphic VT Polymorphic VT | | Amiodarone Check QT interval Lidocaine | Procainamide ┌───────┴───────┐ | Normal QT Long QT If unstable: | | Synchronized Treat as VT Torsades cardioversion | Magnesium

Bradycardia Management:

Bradycardia (HR <60 bpm) | Symptoms or hemodynamic compromise? | ┌─────────────┴─────────────┐ No symptoms Symptomatic | | Observation Atropine 0.5-1mg IV | | Serial monitoring Effective? | | Identify reversible ┌───No───┴───Yes──┐ causes | | Consider: Monitor - Transcutaneous | pacing Treat underlying - Dopamine cause - Isoproterenol | | Consider permanent Temporary pacing pacemaker if | indicated Permanent pacing if indicated

Key Management Principles:

1. Always prioritize hemodynamic stability
2. Treat underlying causes: Electrolyte abnormalities, ischemia, hypoxia, drug effects
3. Consider contraindications: Renal function for drug dosing, structural heart disease for antiarrhythmics
4. Long-term strategy: Prevention of recurrence, stroke risk reduction
5. Patient education: Symptom recognition, when to seek care

Common Precipitating Factors:

• Electrolyte abnormalities (hypokalemia, hypomagnesemia)
• Myocardial ischemia or infarction
• Heart failure exacerbation
• Medication effects or toxicity
• Hyperthyroidism
• Pulmonary embolism
• Sepsis or systemic illness